Balyasny Asset Management
SGNT

Balyasny Asset Management’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Balyasny Asset Management’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-684,585
Closed -$8.33M – 1625
2016
Q1 		$8.33M Buy
684,585
+644,854
+1,623% +$9.04M 0.05% 444
2015
Q4 		$632K Buy
+39,731
New +$626K ﹤0.01% 782
2015
Q3 		– Sell
-17,290
Closed -$420K – 1566
2015
Q2 		$420K Sell
17,290
-21,310
-55% -$511K ﹤0.01% 889
2015
Q1 		$897K Buy
+38,600
New +$1.02M 0.01% 690
2013
Q4 		– Sell
-468,109
Closed -$9.55M – 729
2013
Q3 		$9.55M Buy
468,109
+16,739
+4% +$373K 0.13% 221
2013
Q2 		$9.47M Buy
+451,370
New +$8.07M 0.16% 156

Other funds holding SGNT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Balyasny Asset Management's SGNT Position: Q2 2016 in Review

Balyasny Asset Management sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2016, closing a stake of 684,585 shares — an estimated $8.33M sold.

Balyasny Asset Management first reported a position in SGNT in Q2 2013 and held it in 6 quarters. The position peaked at $9.55M in Q3 2013. 128 funds tracked by Wall St. Rank hold SGNT as of Q2 2016.

  • Balyasny Asset Management reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2016 after selling out during the quarter.
  • Balyasny Asset Management sold 684,585 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2016, an estimated $8.33M.
  • Balyasny Asset Management first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 6 quarters.
  • Balyasny Asset Management's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $9.55M in Q3 2013.
  • 128 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2016.

Based on Balyasny Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.